Recent Updates
Recently added Catalysts

MatriStem PSM

Phase 2

Esophageal Adenocarcinoma | Unknown | Oncology |Integra LifeSciences Holdings Corporation|Last Updated: Nov 3, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment78
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01970306Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold MaterialPHASE2 COMPLETED 78Oct 18, 2013Feb 24, 2023Nov 3, 20234 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Anastomotic Leak.
up to 10 days

Anastomotic leak will be assessed by clinical observation and one postoperative contrast study (thin-barium Gastrografin or Omnipaque swallow)

Secondary Endpoints
Stricture Formation Clinically and by Determination of Dysphagia Score
90 days postoperatively
Number of Participants Who Developed Anastomotic Stenosis
90 days post op
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Surgical interventionEXPERIMENTALPatients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
Interventions
NameTypeDescription
MatriStem PSMDEVICEAll esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Patient 18 years of age or older * Pathologically confirmed Gastric, Gastroesophageal Junction (GEJ) or Esophageal, adenocarcinoma at either MSKCC or a participating site (biopsy may be performed at other institutions but slides must be confirmed at MSKCC or a participating si...

Countries:United States
Unlock Eligibility Criteria